Text Size

A Comparative Study of the Air-Q ILA and the ILMA for Ventilation and Intubation

This study has suspended participant recruitment.
(Study never initiated.)
Sponsor:
Information provided by (Responsible Party):
Orlando Hung, Capital District Health Authority, Canada
ClinicalTrials.gov Identifier:
NCT01209559
First received: September 23, 2010
Last updated: October 31, 2011
Last verified: October 2011
History of Changes
  Purpose

The objective of this study is to determine if the glottic view obtained with the air-Q Intubating Laryngeal Airway (air-Q ILA, Cookgas LLC®, Mercury Medical®, Clearwater, FL, USA) is better than that obtained with the traditionally used intubating laryngeal mask airway (LMA FastrachTM or ILMA, LMA North America Inc., San Diego, CA). The study will also compare effectiveness of ventilation.


Condition
Airway Management

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Further study details as provided by Capital District Health Authority, Canada:

Estimated Enrollment: 60
Study Start Date: January 2011
Estimated Study Completion Date: December 2011
Estimated Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
air-Q Intubating Laryngeal Airway
LMA FastrachTM or ILMA

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Healthy ASA class I and II patients scheduled for elective surgery under general anesthesia requiring the use of the LMA.

Criteria

Inclusion Criteria:

  • healthy ASA class I and II patients scheduled for elective surgery under general anesthesia requiring the use of the LMA

Exclusion Criteria:

  • history of acid reflux,
  • a BMI ≥ 40kg.m-2,
  • require endotracheal intubation,
  • have predictors of difficult intubation,
  • not candidates for insertion of an ILMA or LMA, including a mouth opening of less than 2.5 cm,
  • cannot consent to the study
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01209559

Locations
Canada, Nova Scotia
QEII Health Sciences Centre
Halifax, Nova Scotia, Canada, B3H 2Y9
Sponsors and Collaborators
Capital District Health Authority, Canada
  More Information

No publications provided

Responsible Party: Orlando Hung, MD FRCPC, Capital District Health Authority, Canada
ClinicalTrials.gov Identifier: NCT01209559     History of Changes
Other Study ID Numbers: CDHA-RS/2011-156
Study First Received: September 23, 2010
Last Updated: October 31, 2011
Health Authority: Canada: Health Canada

ClinicalTrials.gov processed this record on May 23, 2013